BD Aims to Save Lives by Empowering Women with Choice and Access to Cervical Cancer Screening Self-Collected At Home
Summary
New FDA Submission Includes Self-Collection Swab and High-Tech Laboratory Robotics that Report More High-Risk HPV Strain...
New FDA Submission Includes Self-Collection Swab and High-Tech Laboratory Robotics that Report More High-Risk HPV Strains Than Any Other Test FRANKLIN LAKES, N.J. , July 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced it has submitted an application to the U.S. Food and Drug Administration for a new, at-home human papillomavirus (HPV) test that enables patients to self-collect a sample in the comfort of their own home using a swab the size of a Q-tip that simplifies processing at the lab and reports more high-risk strains of HPV than any other test on the market today.